ID   IPH-926
AC   CVCL_A625
SY   IPH926
DR   cancercelllines; CVCL_A625
DR   Cosmic; 1179081
DR   DSMZ; ACC-827
DR   DSMZCellDive; ACC-827
DR   GEO; GSE28089
DR   Wikidata; Q54897973
RX   PubMed=19191266;
RX   PubMed=22118813;
RX   PubMed=22945757;
RX   PubMed=24344720;
RX   PubMed=25757734;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Characteristics: Expresses high level of ABCB1 mRNA (PubMed=22118813).
CC   Doubling time: ~2 weeks (PubMed=19191266); 200 hours (Note=In the first 1-2 weeks), 80-120 hours (Note=After 2 weeks) (DSMZ=ACC-827).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1748; CDH1; Zygosity=Heterozygous (PubMed=19191266).
CC   Sequence variation: Mutation; HGNC; HGNC:1748; CDH1; Simple; p.Val82fs*13 (c.240_241insGGTG); Zygosity=Heterozygous (PubMed=19191266).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=22945757).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ=ACC-827; PubMed=22118813
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 12,22
ST   D19S433: 16
ST   D21S11: 30
ST   D2S1338: 19,20
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 19
ST   Penta D: 9
ST   Penta E: 11,12
ST   TH01: 6 (DSMZ=ACC-827)
ST   TH01: 7 (PubMed=22118813)
ST   TPOX: 8,10
ST   vWA: 15,16
DI   NCIt; C7950; Invasive breast lobular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 17
//
RX   PubMed=22945757; DOI=10.1038/labinvest.2012.126;
RA   Christgen, Matthias
RA   Noskowicz, Monika
RA   Heil, Charlotte
RA   Schipper, Elisa
RA   Christgen, Henriette
RA   Geffers, Robert
RA   Kreipe, Hans-Heinrich
RA   Lehmann, Ulrich
RT   "IPH-926 lobular breast cancer cells harbor a p53 mutant with
RT   temperature-sensitive functional activity and allow for profiling of
RT   p53-responsive genes.";
RL   Lab. Invest. 92:1635-1647(2012).
//
RX   PubMed=22118813; DOI=10.1016/j.canlet.2011.09.038;
RA   Krech, Till
RA   Scheuerer, Elisa
RA   Geffers, Robert
RA   Kreipe, Hans-Heinrich
RA   Lehmann, Ulrich
RA   Christgen, Matthias
RT   "ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of
RT   IPH-926 human lobular breast cancer cells.";
RL   Cancer Lett. 315:153-160(2012).
//
RX   PubMed=24344720; DOI=10.1111/cas.12276; PMCID=PMC7654255;
RA   Christgen, Matthias
RA   Geffers, Robert
RA   Kreipe, Hans-Heinrich
RA   Lehmann, Ulrich
RT   "IPH-926 lobular breast cancer cells are triple-negative but their
RT   microarray profile uncovers a luminal subtype.";
RL   Cancer Sci. 104:1726-1730(2013).
//
RX   PubMed=25757734; DOI=10.1186/s13058-015-0517-z; PMCID=PMC4320436;
RA   Christgen, Matthias
RA   Derksen, Patrick W.B.
RT   "Lobular breast cancer: molecular basis, mouse and cellular models.";
RL   Breast Cancer Res. 17:16.1-16.9(2015).
//
RX   PubMed=19191266; DOI=10.1002/path.2495;
RA   Christgen, Matthias
RA   Bruchhardt, Henriette
RA   Hadamitzky, Catarina
RA   Rudolph, Cornelia
RA   Steinemann, Doris
RA   Gadzicki, Dorothea
RA   Hasemeier, Britta
RA   Romermann, Daniel
RA   Focken, Tim
RA   Krech, Till
RA   Ballmaier, Matthias
RA   Schlegelberger, Brigitte
RA   Kreipe, Hans-Heinrich
RA   Lehmann, Ulrich
RT   "Comprehensive genetic and functional characterization of IPH-926: a
RT   novel CDH1-null tumour cell line from human lobular breast cancer.";
RL   J. Pathol. 217:620-632(2009).
//